Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2014

01-09-2014 | Case Report

AML M7 Misdiagnosed as ALL

Authors: Jayashri Chaudhari, Antia Borges, Shweta Bansal, Pravin Mahajan

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2014

Login to get access

Abstract

Hematogones, which are normal precursors of B lymphocytes in the bone marrow, may be mistaken for blast cells on flow cytometry and histology when their numbers increase. We report such a case in a 16 months old male who was unsuccessfully treated for a pre-B cell ALL on the basis of flow cytometry of the bone marrow which showed a substantial population of CD19 and CD10 expressing ‘blast’ cells. A diagnosis of AML M7 was made on a subsequent bone marrow biopsy in which the blast cells expressed CD61 and Factor VIII, while they were negative for CD10 and CD20. Also present were a few CD10 and CD20 expressing small lymphoid cells, which were interpreted as hematogones. This report reiterates the problem of mistaking hematogones for ‘blast’ cells on flow cytometry, especially in the marrow of very young children where hematogones are often prominent.
Literature
1.
go back to reference McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH (2001) Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 98(8):2498–2507PubMedCrossRef McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH (2001) Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 98(8):2498–2507PubMedCrossRef
2.
go back to reference Rimsza LM, Larson RS, Winter SS, Foucar K, Chong YY, Garner KW, Leith CP (2000) Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol 4(1):66–75CrossRef Rimsza LM, Larson RS, Winter SS, Foucar K, Chong YY, Garner KW, Leith CP (2000) Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol 4(1):66–75CrossRef
3.
go back to reference Moreno-Madrid F, Uberos J, Díaz-Molina M, Ramírez-Arredondo A, Jiménez-Gámiz P, Molina-Carballo A (2008) The presence of precursors of benign pre-B lymphoblasts (hematogones) in the bone marrow of a paediatric patient with cytomegalovirus infection. Clin Med Oncol 2:437–439PubMedPubMedCentral Moreno-Madrid F, Uberos J, Díaz-Molina M, Ramírez-Arredondo A, Jiménez-Gámiz P, Molina-Carballo A (2008) The presence of precursors of benign pre-B lymphoblasts (hematogones) in the bone marrow of a paediatric patient with cytomegalovirus infection. Clin Med Oncol 2:437–439PubMedPubMedCentral
4.
go back to reference Richard G, Brody J, Sun T (1993) A case of acute megakaryocytic leukemia with hematogones. Leukemia 7(11):1900–1903PubMed Richard G, Brody J, Sun T (1993) A case of acute megakaryocytic leukemia with hematogones. Leukemia 7(11):1900–1903PubMed
Metadata
Title
AML M7 Misdiagnosed as ALL
Authors
Jayashri Chaudhari
Antia Borges
Shweta Bansal
Pravin Mahajan
Publication date
01-09-2014
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-013-0326-4

Other articles of this Special Issue 1/2014

Indian Journal of Hematology and Blood Transfusion 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine